Bausch Health Companies Inc. (BHC) Form 8-K — Oct 28, 2026
Bausch Health delivered a strong Q3 2026, with consolidated revenue of $2.94 billion (up 10% reported, 8% organic) and adjusted EPS of $1.77 versus $1.16 a year ago, a 53% increase. Adjusted EBITDA attributable to Bausch Health rose 32% to $1,305 million, and ex-B+L quarterly EBITDA exceeded $1 billion for the first time. The company raised full-year 2026 guidance across revenue, adjusted EBITDA, and adjusted cash flows from operations, now expecting consolidated revenue of $10.975-$11.175 billion (7-9% growth) and adjusted EBITDA of $4.315-$4.415 billion (12-14% growth). Operating cash flow more than doubled to $813 million, supporting over $500 million of net debt reduction in the quarter.
Key figures
- Eps
- 1.15
- Revenue
- 2941000000
- Guidance
- FY2026 consolidated revenue $10.975-$11.175B (7-9% growth), Adjusted EBITDA $4.315-$4.415B (12-14% growth), Adjusted Cash Flows from Operations $1.600-$1.675B; BHC ex-B+L revenue $5.525-$5.625B, Adjusted EBITDA $3.225-$3.275B
- Net Income
- 436000000
- Total Debt
- 20637000000
- Revenue Yoy
- 10% reported / 8% organic
- Cash Position
- 2485000000
- Adjusted eps
- $1.77 vs $1.16 prior year (+53%)
- Adjusted ebitda
- $1,305 million vs $986 million (+32%)
- Net debt reduction
- more than $500 million in the quarter
- Operating cash flow
- $813 million (+101% YoY)
- Share repurchase authorization
- $50 million
- Goodwill impairment nine months
- $1,426 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.